Journal
CLINICAL CANCER RESEARCH
Volume 16, Issue 19, Pages 4702-4710Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-0939
Keywords
-
Categories
Funding
- Glaxo Smith Klein
- Boehringer-Ingelheim
- Genentech
- Wyeth
- Bristol Myers Squibb
- BiPAR/Sanofi Aventis
- NCI [CA058223]
- NIH [R01 CA108794]
- Breast Cancer Research Foundation
- Susan G. Komen for the Cure
- National Cancer Institute at the Dana-Farber/Harvard Cancer Center [CA089393]
- Cogan Family Foundation
- Canadian Breast Cancer Research Foundation
- [5K12CA120780-03]
- NATIONAL CANCER INSTITUTE [P50CA089393, P50CA058223, R01CA108794, K12CA120780] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In contrast to endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, novel agents capable of treating advanced triple-negative breast cancer (TNBC) are lacking. Poly (ADP-ribose) polymerase (PARP) inhibitors are emerging as one of the most promising targeted therapeutics to treat TNBC, with the intended target being DNA repair. PARPs are a family of enzymes involved in multiple cellular processes, including DNA repair. TNBC shares multiple clinico-pathologic features with BRCA-mutated breast cancers, which harbor dysfunctional DNA repair mechanisms. Investigators hypothesized that PARP inhibition, in conjunction with the loss of DNA repair via BRCA-dependent mechanisms, would result in synthetic lethality and augmented cell death. This hypothesis has borne out in both preclinical models and in clinical trials testing PARP inhibitors in both BRCA-deficient and triple-negative breast cancer. The focus of this review includes an overview of the preclinical rationale for evaluating PARP inhibitors in TNBC, the presumed mechanism of action of this novel therapeutic class, promising results from several influential clinical trials of PARP inhibition in advanced breast cancer (both TNBC and BRCA deficient), proposed mechanisms of acquired resistance to PARP inhibitors, and, finally, concludes with current challenges and future directions for the development of PARP inhibitors in the treatment of breast cancer. Clin Cancer Res; 16(19); 4702-10. (C) 2010 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available